Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Moodys

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,495,541

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,495,541 protect, and when does it expire?

Patent 6,495,541 protects RUBRACA and is included in one NDA.

This patent has fifty-two patent family members in thirty-nine countries.

Summary for Patent: 6,495,541
Title: Tricyclic inhibitors of poly(ADP-ribose) polymerases
Abstract:Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapuetics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and nuerodegenerative disease. ##STR1## As cancer therapuetics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
Inventor(s): Webber; Stephen Evan (San Diego, CA), Canan-Koch; Stacie S. (La Jolla, CA), Tikhe; Jayashree (San Diego, CA), Thoresen; Lars Henrik (College Station, TX)
Assignee: Agouron Pharmaceuticals, Inc. (La Jolla, CA)
Application Number:09/479,896
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,495,541

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Moodys
Medtronic
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.